VWR (VWR) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
VWR Acquires Reliable Biopharmaceutical and BioArra
November 3, 2016 6:10 AM EDTRADNOR, Pa., Nov. 3, 2016 /PRNewswire/ --Â VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, announced today the acquisition of two companies, Reliable Biopharmaceutical and BioArra.
Reliable Biopharmaceutical, a manufacturer of high quality active pharmaceutical ingredients (APIs) and high purity ingredients (HPIs) such as cGMP excipients and advanced intermediates for the biopharmaceutical industry, enhances VWR's growing custom chemical and biochemical manufacturing portfolio. Reliable Biopharmaceutical offers... More
VWR Corporation Reports Third Quarter 2016 Financial Results
November 3, 2016 6:00 AM EDTRADNOR, Pa., Nov. 3, 2016 /PRNewswire/ -- VWR Corporation (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, today reported its financial results for the third quarter ended September 30, 2016.
Highlights:
3Q16 diluted EPS of $0.31 vs. $0.08 in 3Q15, 3Q16 Adjusted EPS of $0.44 vs. $0.38 in 3Q15. Third quarter net sales of $1.14 billion, up 3.7% year-over-year, and up 1.6% on an organic basis.... More


